Timing of hormone therapy use impacts alzheimer's risk

Timing of hormone therapy use impacts alzheimer's risk
Use of hormone therapy within five years of menopause is associated with a reduction in the risk of Alzheimer's disease, according to a study published online Oct. 24 in Neurology.

(HealthDay)—Use of hormone therapy (HT) within five years of menopause is associated with a reduction in the risk of Alzheimer's disease (AD), according to a study published online Oct. 24 in Neurology.

Huibo Shao, from Weill Cornell Medical College in New York City, and colleagues examined whether the timing or type of HT impacts its association with AD. A cohort of 1,768 women from the Cache County Study who provided a detailed history of age at and use of HT were followed between 1995 and 2006. One hundred seventy-six women developed incident AD during this period.

The researchers found that use of any type of HT within five years of menopause was associated with a significant 30 percent reduction in the risk of AD, particularly if HT was used for 10 years or more. There was no reduction in AD risk seen for women who initiated HT five years or more after menopause. who began "opposed" estrogen-progestin compounds within three years preceding the Cache County Study baseline had an increased risk of AD (adjusted hazard ratio, 1.93; 95 percent confidence interval, 0.94 to 3.96), which was similar to that reported in randomized trial participants assigned to opposed HT.

"Association of HT use and risk of AD may depend on timing of use. Although possibly beneficial if taken during a critical window near menopause, HT (especially opposed compounds) initiated in later life may be associated with increased risk," the authors write. "The relation of AD risk to timing and type of HT deserves further study."

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

VTE risk varies by hormone therapy formulation

date Sep 18, 2012

(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral ...

The Women's Health Initiative: An unforgettable decade

date May 31, 2012

The 10-year anniversary of the historic Women's Health Initiative (WHI) Hormone Therapy Trial report, which radically changed the practice of women's health, will be commemorated in July 2012. In anticipation of this event, ...

Recommended for you

Helpful app for people with dementia

date Apr 21, 2015

Bangor University is providing expertise to support the development and effectiveness of 'Book of You', an 'app' being welcomed as having the potential to revolutionise reminiscence therapy for people with dementia.

New approaches for early diagnosis of Alzheimer's

date Apr 17, 2015

Mild cognitive impairment, or MCI, may be one of Alzheimer's earliest signs. The subtle changes of MCI include problems with memory, language, thinking and judgment and a subjective sense that mental function ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.